229
Participants
Start Date
October 6, 2014
Primary Completion Date
March 26, 2018
Study Completion Date
September 3, 2019
Ibrutinib
Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
Obinutuzumab
Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
Chlorambucil
Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
Site Reference ID/Investigator# 0241, La Jolla
Site Reference ID/Investigator# 0844, Fort Myers
Site Reference ID/Investigator# 0763, West Palm Beach
Site Reference ID/Investigator# 071, Louisville
Site Reference ID/Investigator# 0712, Las Vegas
Site Reference ID/Investigator# 0845, Cincinnati
Site Reference ID/Investigator# 0868, Chattanooga
Site Reference ID/Investigator# 0123, Nashville
Site Reference ID/Investigator #0503, Woolloongabba
Site Reference ID/Investigator# 0650, Adelaide
Site Reference ID/Investigator# 0888, Ballarat
Site Reference ID/Investigator# 0193, Box Hill
Site Reference ID/Investigator# 0633, Fitzroy
Site Reference ID/Investigator# 0170, Heidelberg
Site Reference ID/Investigator# 0352, Linz
Site Reference ID/Investigator# 0869, Salzburg
Site Reference ID/Investigator# 0559, Leuven
Site Reference ID/Investigator# 0850, Turnhout
Site Reference ID/Investigator# 018, Edmonton
Site Reference ID/Investigator# 0564, Hradec Králové
Site Reference ID/Investigator# 0854, Prague
Site Reference ID/Investigator# 0769, Pessac
Site Reference ID/Investigator# 0520, Nantes
Site Reference ID/Investigator# 0775, Vandœuvre-lès-Nancy
Site Reference ID/Investigator# 0855, Bayonne
Site Reference ID/Investigator# 0573, Haifa
Site Reference ID/Investigator# 0577, Jerusalem
Site Reference ID/Investigator# 0579, Jerusalem
Site Reference ID/Investigator# 0575, Petah Tikva
Site Reference ID/Investigator# 0856, Tel Aviv
Site Reference ID/Investigator# 0875, Ẕerifin
Site Reference ID/Investigator# 0860, Florence
Site Reference ID/Investigator# 0523, Milan
Site Reference ID/Investigator# 0581, Milan
Site Reference ID/Investigator# 0584, Milan
Site Reference ID/Investigator# 0524, Modena
Site Reference ID/Investigator# 0582, Novara
Site Reference ID/Investigator# 0732, Roma
Site Reference ID/Investigator# 0859, Siena
Site Reference ID/Investigator# 0663, Auckland
Site Reference ID/Investigator# 662, Auckland
Site Reference ID/Investigator# 0586, Hamilton
Site Reference ID/Investigator# 0592, Brzozów
Site Reference ID/Investigator# 0531, Lodz
Site Reference ID/Investigator# 0708, Nizhny Novgorod
Site Reference ID/Investigator# 0707, Ryazan
Site Reference ID/Investigator# 0881, Saint Petersburg
Site Reference ID/Investigator# 710, Saint Petersburg
Site Reference ID/Investigator# 304, Yaroslavl
Site Reference ID/Investigator# 0604, L'Hospitalet de Llobregat
Site Reference ID/Investigator# 0536, Majadahonda
Site Reference ID/Investigator# 0533, Barcelona
Site Reference ID/Investigator# 0534, Barcelona
Site Reference ID/Investigator# 0535, Barcelona
Site Reference ID/Investigator# 0537, Madrid
Site Reference ID/Investigator# 0864, Madrid
Site Reference ID/Investigator# 0874, Madrid
Site Reference ID/Investigator# 0790, Salamanca
Site Reference ID/Investigator# 0870, Borås
Site Reference ID/Investigator# 0865, Luleå
Site Reference ID/Investigator# 0631, Lund
Site Reference ID/Investigator# 0632, Stockholm
Site Reference ID/Investigator# 0678, Istanbul
Site Reference ID/Investigator# 0608, Ankara
Site Reference ID/Investigator# 606, Ankara
Site Reference ID/Investigator# 0889, Denizli
Site Reference ID/Investigator# 0601, Izmir
Site Reference ID/Investigator# 0866, Samsun
Site Reference ID/Investigator# 0867, Harlow
Site Reference ID/Investigator# 0365, London
Site Reference ID/Investigator# 0543, London
Lead Sponsor
Pharmacyclics LLC.
INDUSTRY